Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops
NCT ID: NCT02138461
Last Updated: 2014-09-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
211 participants
OBSERVATIONAL
2013-10-31
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension
NCT00541242
Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient Target Pressures With Bimatoprost 0.03% in Glaucoma
NCT00487214
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
NCT00347841
Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma
NCT01361841
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
NCT01830140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
bimatoprost
These patients take bimatoprost topically for glaucoma.
No interventions assigned to this group
latanoprost group
These patients take latanoprost topically for glaucoma.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
MDbackline, LLC
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John A. Hovanesian, MD
Role: PRINCIPAL_INVESTIGATOR
UCLA Jules Stein Eye Institute
Savak Teymoorian, MD
Role: PRINCIPAL_INVESTIGATOR
Harvard Eye Associates
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Harvard Eye Associates
Laguna Hills, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JH-ALG-MDB-1301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.